

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
WO 2005/079868 A3(51) International Patent Classification<sup>7</sup>: A61K 51/04, 31/519, 31/4985, C07D 487/04, 471/16, A61P 5/02

(74) Agent: DOLTON, Peter; GlaxoSmithKline, CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(21) International Application Number:

PCT/GB2005/000432

(22) International Filing Date: 9 February 2005 (09.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/544,758 13 February 2004 (13.02.2004) US

(71) Applicants (for all designated States except US): SB PHARMCO PUERTO RICO INC [US/US]; The Prentice Hall Corp. System of PR Inc, c/o FGR Corporate Services Inc, BBV Tower 8th Floor, 254 Munoz Rivera Avenue, San Juan, PUERTO RICO 009 (US). NEUROCRINE BIOSCIENCES INC [US/US]; 12790 El Camino Real, San Diego, California 92130 (US).

(71) Applicant (for MG only): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SLEE, Deborah [US/US]; Neurocrine Biosciences Inc, 12790 El Camino Real, San Diego, California 92130 (US). GRIGORIADIS, Dimitri [CA/US]; Neurocrine Biosciences Inc, 12790 El Camino Real, San Diego, CA 92130 (US). WILLIAMS, John [US/US]; Neurocrine Biosciences Inc, 12790 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report

(88) Date of publication of the international search report: 26 January 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CRF RECEPTOR ANTAGONISTS, THEIR PREPARATIONS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES

(57) Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals. CRF receptor antagonists which are labeled with a positron emitting isotope for use in PET are also disclosed.